Sinopharm Group Co. Ltd. disclosed its Monthly Return for Equity Issuer for the period ended 30 June 2026, confirming a stable capital structure and full compliance with Hong Kong Stock Exchange public-float requirements.

Share Capital Structure • Authorised / Registered Capital: 3.12 billion shares with a par value of RMB 1 each, translating into authorised share capital of RMB 3.12 billion. • Issued Shares: 3.12 billion, split between 1.34 billion H shares and 1.78 billion domestic shares. • Treasury Shares: Zero. • Monthly Movement: No increase or decrease was recorded in either authorised or issued share capital during June 2026.

Public-Float Compliance • The company confirmed adherence to Main Board Rule 13.32B, maintaining at least 25 % public float for its H shares. • No share repurchases, cancellations, or treasury transactions occurred that would affect float levels.

Equity Instruments and Other Arrangements • No share options, warrants, convertible securities or other agreements to issue additional shares were outstanding or executed in the month.

Administrative Details • The return was submitted to Hong Kong Exchanges and Clearing Limited on 06 July 2026 by Company Secretary Wu Yijian.

The absence of share-capital changes and the confirmed public-float sufficiency underscore Sinopharm’s stable equity position as at end-June 2026.